Table 2.
VWF and ATDAMTS13 levels ad activity reported in critically ill COVID-19 patients with and without preexisting comorbidities. Normal reference VWF antigen range (%) 42–136 a. Normal reference VWF activity range (%) 42–168 b. Normal ADAMTS13 antigen reference range (%) 40–130 c. Normal ADAMTS13 activity reference range (%) 50–150 d. The value is reported as median (interquartile range) e.
| Location | Patient Characteristics (n) | Mean Age (years) | VWF Antigen (%) a Mean (Min–Max) | VWF Activity (%) b Mean (Min–Max) | ADAMTS13 (%) c Mean (Min–Max) | ADAMTS13 Activity (%) d Mean (Min–Max) | Author |
|---|---|---|---|---|---|---|---|
| Italy | Intubated COVID-19 patients (11) | – | 529 (210–863) | 387 (195–550) | – | – | Panigada et al., 2020 [146] |
| The Netherlands | COVID-19 patients admitted to ICU (12) | 61.8 | 408.0 | 374.0 | 48.0 | – | Huisman et al., 2020 [168] |
| France | Patients with radiological signs of interstitial pneumonia (212) | 63.9 | 361.0 | – | – | – | Rauch et al., 2020 [169] |
| Germany e | COVID-19 patients with high severity (150) | 63.0 | 455 (350–521) | 328 (212–342) | – | – | Helms et al., 2020 [128] |
| Italy e | COVID-19 patients with high severity (19) | 59.0 | 476 (381–537) | 388 (328–438) | – | 55 (42–68) | Mancini et al., 2021 [144] |
| United Kingdom e | Intubated ICU patients (24) | 65.0 | 350 (302–433) | – | – | – | Ladikou et al., 2020 [170] |
| Ireland | COVID-19 patients admitted to ICU (28) | 55.0 | 690.2 (467–848.4) | – | – | – | Ward et al., 2021 [171] |
| France e | Patients with critical form of COVID-19 in ICU (89) | 62.0 | 507 (428–596) | 399 (333–537) | – | – | Philippe et al., 2021 [172] |
| France e | COVID-19 patients with Venous thromboembolic events (38) | 63.0 | 522 (411–672) | – | – | 59 (38.8–70.5) | Delrue et al., 2021 [173] |
| Italy | Intubated ICU patients (6) | 62.0 | 634 (455–772) | 450 (339–496) | 37.3 (24–56) | – | Morici et al., 2020 [148] |
| United States | Intubated ICU patients (48) | 64.0 | 565.0 | 390.0 | – | – | Goshua et al., 2020 [138] |
| Italy | Patients with COVID-19 pneumonia (37) | 61.8 | 280.8 | 265.1 | – | – | Taus et al., 2020 [174] |
| Spain | ICU patients with the history of hypertension and diabetes mellitus (22) | 68.0 | 368.6 | – | – | 38.9 | Marco et al., 2021 [175] |
| Italy e | Patients with novel coronavirus pneumonia (10) | 61.0 | 324.1 | 341.5 | 69.0 | – | De Cristofaro 2021 [176] |
| Spain e | COVID-19 patients with cardiovascular disease and diabetes (23) | 64.0 | 306.0 | – | 47.3 | – | Blasi et al., 2020 [177] |
| Germany | COVID-19 patients with mild to moderate severity (75) | 66.0 | 403.0 | – | 67.8 | – | Doevelaar et al., 2021 [145] |
| Italy | Patients with the history of hypertension and diabetes (19) | 69.0 | 331.4 | 321.7 | – | – | Ruberto et al., 2020 [178] |
| United States e | COVID-19 non-survivors (90) | 72.5 | 441.0 | 321.0 | – | 48.8 | Sweeney et al., 2020 [179] |
| Spain e | Severe COVID-19 patients (50) | – | 355 (267–400) | – | 53.2 (38.8–65.3) | – | Rodríguez et al., 2021 [180] |
| Italy | COVID-19 non-survivors (9) | 72.0 | 395.5 | – | 32.2 | – | Bazzan et al., 2020 [126] |
| Belgium | COVID-19 patients admitted to ICU (9) | 57–64 | 475.0 | 429.0 | 45.0 | – | Hardy et al., 2020 [181] |
| United States e | 17 | 42–58 | 448 (362–529) | 313 (190–347) | – | – | Masi et al., 2020 [182] |
| Sweden e | Patients with COVID-19 high care (12) | 53–69 | 425 (321–465) | – | 57 (42–62) | – | Meijenfeldt et al., 2021 [183] |
| Germany | COVID-19 non-survivors (5) | 78.0 | 260.4 | 217.6 | – | 43.3 | De Jongh et al., 2021 [184] |
| France e | COVID-19 patients admitted to ICU (22) | – | 456 (402–493) | 355 (297–416) | 458 (364–615) | – | Pascreau et al., 2021 [185] |